- Tytuł:
-
Szczęście i ciężka praca w opracowywaniu leków
Luck and hard work in drug discovery - Autorzy:
- Koroniak, Łukasz
- Powiązania:
- https://bibliotekanauki.pl/articles/972288.pdf
- Data publikacji:
- 2020
- Wydawca:
- Polskie Towarzystwo Chemiczne
- Tematy:
-
chemoterapia
paclitaxel
enzalutamide
receptor androgenowy
rak prostaty
opracowywanie leków
chemotherapy
androgen receptor
prostate cancer
drug discovery - Opis:
- Luck is one of the critical factors determining outcome of many activities we are involved in. In chemistry, and specifically in drug discovery a strike of luck can determine a successful study outcome leading to an approval of potentially blockbuster drug consequently offering a new treatment option for patients in need. On the other hand, lack of luck can often result in termination of activities, wasted resources and years of studies and often have negative impact on a fate of companies and its employees. In a similar fashion, hard work is critical for one’s success. It is not meant in a literal fashion, but rather from the perspective of “going the extra mile” in scientific research and development. It is meant as a proper approach to analysis of study outcome and understanding the reasons “why”, rather than accepting simply yes/no outcomes. Below article discusses two instances where certain level of luck and extra effort invested in understanding of widely available results led to development of two novel therapeutics in oncology field. Described stories deal with development of Abraxane, novel formulation of paclitaxel commercialized by Abraxis Bioscience as well as enzalutamid (Xtandi®) discovered at UCLA and developed and commercialized by Medivation and Astellas Pharma.
- Źródło:
-
Wiadomości Chemiczne; 2020, 74, 3-4; 135-144
0043-5104
2300-0295 - Pojawia się w:
- Wiadomości Chemiczne
- Dostawca treści:
- Biblioteka Nauki
Artykuł